<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01874093</url>
  </required_header>
  <id_info>
    <org_study_id>CLP1050035</org_study_id>
    <nct_id>NCT01874093</nct_id>
  </id_info>
  <brief_title>IMPACT- 24Bt Post Mech. Thrombectomy and/or rtPA TRIAL IMPlant Augmenting Cerebral Blood Flow 24 Hours From Stroke Onset</brief_title>
  <acronym>IMPACT-24Bt</acronym>
  <official_title>A Multi-center, Rand., Double Blind, Sham Control, Parallel Arm Post Mech. Thrombectomy and/or rtPA Trial to Assess Safety and Effectiveness of the Ischemic Stroke System, as an Adjunct to Stand. of Care in Subjects With Acute Isch. Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BrainsGate</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BrainsGate</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to assess the safety and effectiveness of SPG&#xD;
      stimulation with the ISS in a 24 hour window, in patients with an acute ischemic stroke in&#xD;
      the anterior circulation, who received Mechanical Thrombectomy and/or IV-rtPA and Standard of&#xD;
      Care.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a multi-center, multinational, randomized, double blind, sham control,&#xD;
      adjunctive to Standard of Care, parallel arm study and will include ongoing DSMB review of&#xD;
      accumulated safety data.&#xD;
&#xD;
      The study has three phases:&#xD;
&#xD;
      Phase I - Implantation Safety Assessment&#xD;
&#xD;
        -  Number of patients: 20 (at least 10 implantations)&#xD;
&#xD;
        -  Implanters: only certified implanters who already performed implantation of ISS in&#xD;
           previous studies&#xD;
&#xD;
        -  Continue to the next phase if there are no serious procedure complications related to&#xD;
           IV-rtPA (as determined by the implanter). Otherwise, implement retirements and continue&#xD;
           only after DSMB approval.&#xD;
&#xD;
      DSMB meetings: after 10 implantations&#xD;
&#xD;
      Phase II - Symptomatic Intracranial Hemorrhage Assessment (sICH):&#xD;
&#xD;
        -  Number of patients: 50 (additional 30)&#xD;
&#xD;
        -  Implanters: all certified implanters&#xD;
&#xD;
        -  Verify no clinically meaningful difference between treated and control. A clinically&#xD;
           meaningful difference is a difference of more than 3 sICH cases within the first 5 days&#xD;
           of treatment, in the treated arm compared to the control arm.&#xD;
&#xD;
      In case of clinically meaningful difference, implement retirements.&#xD;
&#xD;
        -  Continue to phase III after DSMB approval.&#xD;
&#xD;
        -  DSMB meetings: after 30 and 50 patients&#xD;
&#xD;
      Phase III - Entire study population, DSMB meetings at 100 and 150 patients&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">June 2018</completion_date>
  <primary_completion_date type="Actual">June 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Distribution of patients across the ordinal modified Rankin scale (mRS)</measure>
    <time_frame>90 days</time_frame>
    <description>The primary effectiveness endpoint will be the modified Rankin Scale (mRS) evaluated by the site on Day 90±7.&#xD;
The statistical analysis of the primary effectiveness endpoint will be: Sliding Dichotomous mRS.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Distribution of patients with NIHSS best language score ≥ 2 at screening across the ordinal modified Rankin scale (mRS)</measure>
    <time_frame>90 days</time_frame>
    <description>The secondary effectiveness endpoint will be the modified Rankin Scale (mRS) evaluated by the site on Day 90±7 for patients with NIHSS best language score ≥ 2 at screening.&#xD;
The statistical analysis of the primary effectiveness endpoint will be: Sliding Dichotomous mRS.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Active Stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INS implantation, 5 Days of Ischemic Stroke System (ISS) Stimulation + Standard of Care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Stimulation</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham implantation, 5 Days of Sham Stimulation + Standard of Care</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>The Ischemic Stroke System</intervention_name>
    <description>SPG stimulation and standard of care</description>
    <arm_group_label>Active Stimulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham control</intervention_name>
    <description>Sham stimulation and standard of care</description>
    <arm_group_label>Sham Stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age: ≥ 40 years and ≤ 80 years for male and 85 for female subjects&#xD;
&#xD;
          2. Clinical diagnosis of an acute ischemic stroke in the Carotid, Middle or Anterior&#xD;
             Cerebral Artery territories based on general physical examination and neurological&#xD;
             examination.&#xD;
&#xD;
          3. Imaging findings demonstrating signs of ischemia (or total arterial occlusion prior to&#xD;
             the MT procedure) in the anterior circulation, consistent with the clinical diagnosis.&#xD;
&#xD;
          4. Performance of MT within &lt;8 hours from stroke onset and/or administration of IV-rtPA&#xD;
             within ≤ 4.5 hours from stroke onset.&#xD;
&#xD;
          5. NIHSS ≥ 7 and ≤ 18 within 2 hours prior to implantation.&#xD;
&#xD;
          6. Ability to initiate treatment within&#xD;
&#xD;
             ≤ 24 hours from stroke onset.&#xD;
&#xD;
          7. Signed informed consent from patient him/herself or legally authorized representative&#xD;
             if applicable.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Neuro-imaging evidence of any intracranial hemorrhage (including suspect of Sub&#xD;
             Arachnoid Hemorrhage) or hemorrhagic transformation of brain infarct or other&#xD;
             significant abnormality (e.g. tumor, abscess)&#xD;
&#xD;
          2. Massive stroke, defined as acute parenchymal lesion with effacement of cerebral sulci&#xD;
             in over 2/3 of the MCA territory.&#xD;
&#xD;
          3. Acute stroke due to lacunar infarct as defined by a clinical syndrome (pure motor&#xD;
             hemiparesis, ataxic hemiparesis, sensorimotor stroke, dysarthria-clumsy hand&#xD;
             syndrome), unless brain imaging demonstrates a relevant lesion &gt; 1.5 cm in size.&#xD;
&#xD;
          4. Clinical signs and symptoms or evidence for a relevant lesion by neuro-imaging of an&#xD;
             acute ischemic stroke in the posterior circulation (Vertebral, Basilar and/or&#xD;
             Posterior Cerebral Artery territories), including but not limited to brain-stem&#xD;
             findings and/or cerebellar findings and/or isolated homonymous hemianopia or cortical&#xD;
             blindness.&#xD;
&#xD;
          5. Minor stroke with non-disabling deficit or rapidly improving neurological symptoms.&#xD;
&#xD;
          6. Clinical signs and symptoms or imaging evidence of bilateral stroke.&#xD;
&#xD;
          7. Treated with IA-rtPA for the current stroke.&#xD;
&#xD;
          8. Complicated MT procedure (including procedures with more than 3 clot removal attempts&#xD;
             (catheter passes), or MT procedure that lasted more than 2 hours)&#xD;
&#xD;
          9. NIHSS level of consciousness score ≥ 2.&#xD;
&#xD;
         10. Previous stroke in the last 6 months or previous stroke with existing sequelae or with&#xD;
             mRS &gt; 0 for any reason&#xD;
&#xD;
         11. Pre-existing disability; Pre-existing Modified Rankin Score &gt;1, even if not&#xD;
             stroke-related.&#xD;
&#xD;
         12. Patients with bleeding propensity and/or one of the following: INR≥ 1.8, prolonged&#xD;
             activated partial thromboplastin time (aPTT) ≥ 45 sec., platelets count &lt; 75×109/L&#xD;
             prior to the implantation/sham procedure.&#xD;
&#xD;
         13. Known cerebral arteriovenous malformation, cerebral aneurysm.&#xD;
&#xD;
         14. Seizure at onset.&#xD;
&#xD;
         15. Blood glucose concentration &lt; 60 mg/dL.&#xD;
&#xD;
         16. Clinical suspicion of septic embolus.&#xD;
&#xD;
         17. Uncontrolled hypertension (systolic &gt;185 mmHg and/or diastolic &gt;110 mmHg),&#xD;
             demonstrated on each of three repeated measurements taken within one hour regardless&#xD;
             of whether or not the patient is taking antihypertensive medications.&#xD;
&#xD;
         18. Serious systemic infection.&#xD;
&#xD;
         19. Women known to be pregnant or having a positive or indeterminate pregnancy test.&#xD;
&#xD;
         20. Patients with other implanted neural stimulator/ electronic devices (pacemakers,&#xD;
             etc.).&#xD;
&#xD;
         21. History of SPG ablation ipsilateral to the stroke side.&#xD;
&#xD;
         22. Any condition in the oral cavity that prevents implantation of the INS, such as&#xD;
             patient is intubated, orthodontics or non-hygienic condition.&#xD;
&#xD;
         23. Life expectancy &lt; 1 year from causes other than stroke.&#xD;
&#xD;
         24. Participating in any other therapeutic investigational trial within the last 30 days.&#xD;
&#xD;
         25. Known sensitivity to any medication to be used during study.&#xD;
&#xD;
         26. Subjects who have a clinically significant or unstable medical or surgical condition&#xD;
             that may preclude safe and complete study participation. Conditions may include:&#xD;
             cardiovascular, vascular, pulmonary, hepatic, renal or neurological (other than acute&#xD;
             ischemic stroke), or neoplastic diseases, as determined by medical history, physical&#xD;
             examination, laboratory tests, or ECG.&#xD;
&#xD;
         27. Subjects who, in the judgment of the investigator, are likely to be non-compliant or&#xD;
             uncooperative during the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eyal Shai</last_name>
    <role>Study Director</role>
    <affiliation>BrainsGate</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <removed_countries>
    <country>Finland</country>
  </removed_countries>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>June 5, 2013</study_first_submitted>
  <study_first_submitted_qc>June 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2013</study_first_posted>
  <last_update_submitted>June 24, 2018</last_update_submitted>
  <last_update_submitted_qc>June 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

